Cargando…
Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
OBJECTIVE: Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727755/ https://www.ncbi.nlm.nih.gov/pubmed/29318157 http://dx.doi.org/10.1155/2017/1249729 |
_version_ | 1783285949639163904 |
---|---|
author | Dørflinger, Gry Høst Holt, Charlotte Brink Thiel, Steffen Østergaard, Jakob Appel Hansen, Troels Krarup |
author_facet | Dørflinger, Gry Høst Holt, Charlotte Brink Thiel, Steffen Østergaard, Jakob Appel Hansen, Troels Krarup |
author_sort | Dørflinger, Gry Høst |
collection | PubMed |
description | OBJECTIVE: Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration is reversed by improved glycaemic control remains unknown. We investigated the effects of improved glycaemic control on MBL concentration in patients with type 1 diabetes. METHODS: We measured MBL, fructosamine, and HbA(1c)at baseline and after 6 weeks in 52 type 1 diabetic patients following the change from conventional insulin therapy to insulin pump therapy. RESULTS: After initiation of insulin pump therapy, the total daily insulin dose was significantly reduced (from 51 ± 18 IE/day to 39 ± 13 IE/day, P < 0.0001). There was a significant decrease in HbA(1c) from 8.6% to 7.7% (from 70 mmol/mol to 61 mmol/mol, P < 0.0001) and in fructosamine levels (from 356 μmol/L to 311 μmol/L, P < 0.0001). MBL levels decreased by 10% from 2165 μg/L (IQR 919–3389 μg/L) at baseline to 1928 μ/L (IQR 811–2758 μg/L) at follow-up (P = 0.005), but MBL change was not significantly correlated with changes in insulin dose, HbA(1c), or fructosamine. CONCLUSIONS: MBL concentration decreased following the initiation of insulin pump therapy in patients with type 1 diabetes and did not correlate with changes in glycaemic control. |
format | Online Article Text |
id | pubmed-5727755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-57277552018-01-09 Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes Dørflinger, Gry Høst Holt, Charlotte Brink Thiel, Steffen Østergaard, Jakob Appel Hansen, Troels Krarup J Diabetes Res Clinical Study OBJECTIVE: Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration is reversed by improved glycaemic control remains unknown. We investigated the effects of improved glycaemic control on MBL concentration in patients with type 1 diabetes. METHODS: We measured MBL, fructosamine, and HbA(1c)at baseline and after 6 weeks in 52 type 1 diabetic patients following the change from conventional insulin therapy to insulin pump therapy. RESULTS: After initiation of insulin pump therapy, the total daily insulin dose was significantly reduced (from 51 ± 18 IE/day to 39 ± 13 IE/day, P < 0.0001). There was a significant decrease in HbA(1c) from 8.6% to 7.7% (from 70 mmol/mol to 61 mmol/mol, P < 0.0001) and in fructosamine levels (from 356 μmol/L to 311 μmol/L, P < 0.0001). MBL levels decreased by 10% from 2165 μg/L (IQR 919–3389 μg/L) at baseline to 1928 μ/L (IQR 811–2758 μg/L) at follow-up (P = 0.005), but MBL change was not significantly correlated with changes in insulin dose, HbA(1c), or fructosamine. CONCLUSIONS: MBL concentration decreased following the initiation of insulin pump therapy in patients with type 1 diabetes and did not correlate with changes in glycaemic control. Hindawi 2017 2017-11-26 /pmc/articles/PMC5727755/ /pubmed/29318157 http://dx.doi.org/10.1155/2017/1249729 Text en Copyright © 2017 Gry Høst Dørflinger et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Dørflinger, Gry Høst Holt, Charlotte Brink Thiel, Steffen Østergaard, Jakob Appel Hansen, Troels Krarup Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_full | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_fullStr | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_full_unstemmed | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_short | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_sort | effect of optimization of glycaemic control on mannan-binding lectin in type 1 diabetes |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727755/ https://www.ncbi.nlm.nih.gov/pubmed/29318157 http://dx.doi.org/10.1155/2017/1249729 |
work_keys_str_mv | AT dørflingergryhøst effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes AT holtcharlottebrink effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes AT thielsteffen effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes AT østergaardjakobappel effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes AT hansentroelskrarup effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes |